Since most of the previous studies were conducted in patients with mild to moderate renal insufficiency, the efficacy and safety of DAPT with potent P2Y12 inhibitors in patients with severe renal insufficiency is unclear [15, 20]. Here, P2RY12 is linked to Renal insufficiency.